Form 4: Replimune Group Director Acquires Stock Options
SEC Form 4 Filing
A director of Replimune Group, Inc. acquired stock options exercisable for 32,000 shares of common stock.
Summary
- On April 1, 2025, Veleka Peeples-Dyer, a director of Replimune Group, Inc., acquired stock options for 32,000 shares.
- The exercise price of the options is $8.40 per share.
- The options vest entirely on April 1, 2026, and expire on April 1, 2035.
- Following the transaction, Peeples-Dyer directly owns 32,000 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing the acquisition of stock options by a company director. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could be seen positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of transaction: Director acquired stock options. |
| 04/01/2026 | Vesting date: Options vest entirely. |
| 04/01/2035 | Expiration date: Options expire. |
| 04/03/2025 | Date of signature. |
Keywords
stock options, Form 4, Replimune Group, director, beneficial ownership, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.